

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of 10

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-JV-5004-U

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number Number - Kind Code* (If known)	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA		US1974/3823135	07-09-1974	Pilgram et al.	
AB		US1996/5512549	04-30-1996	Chen et al.	
AC		US1996/5580979	12-03-1996	Bachovchin	
AD		US1997/5511442	03-25-1997	Habener	
AE		US2000/6156739	12-5-2000	Griffin et al.	
AF		US2000/6166069	12-28-2000	Villhauer	
AG		US2001/6258597-B1	07-10-2001	Bachovchin	
AH		US2001/0022006-A1	09-06-2001	Demuth et al.	
AI		US2001/6303951-B1	10-16-2001	Demuth et al.	
AJ		US2001/6319893-B1	11-20-2001	Demuth et al.	
AK		US2001/0051648-A1	12-13-2001	Demuth et al.	
AL		US2002/0049153-A1	04-25-2002	Brilon et al.	
AM		US2002/0049164-A1	04-25-2002	Demuth et al.	
AN		US2002/0380398-B2	04-30-2002	Kanstrup et al.	
AO		US2002/0082427-A1	06-27-2002	Demuth et al.	
AP		US2002/6448045-B1	09-10-2002	Levine et al.	
AQ		US2002/0196242-A1	12-26-2002	Demuth et al.	
AR		US2002/0196380-A1	12-26-2002	Belzer et al.	
AS		US2002/0500804-B2	12-31-2002	Demuth et al.	
AT		US2003/0008825-A1	01-09-2003	Demuth et al.	
AU		US2003/0548481-B1	04-15-2003	Demuth et al.	
AV		US2003/0092630-A2	05-15-2003	Demuth et al.	
AW		US2003/0119750-A1	06-26-2003	Demuth et al.	
AX		US2003/0130199-A1	07-10-2003	von Hofsten et al.	
AY		US2003/0134802-A1	07-17-2003	Demuth et al.	
AZ		US2003/0135023-A1	07-17-2003	Demuth et al.	
BA		US2003/0145951-A1	08-07-2003	Heiser et al.	
BB		US2003/0163650-A1	08-14-2003	Bachovchin et al.	
BC		US2003/0162820-A1	08-28-2003	Demuth et al.	
BD		US2003/0166578-A1	09-04-2003	Arch et al.	
BE		US2003/0620910-B1	09-16-2003	Celas et al.	
BF		US2003/0176357-A1	09-18-2003	Pospisilik et al.	
BG		US2003/0199451-A1	10-23-2003	Mogensen et al.	
BH		US2003/0199672-A1	10-23-2003	Knudsen et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including review, preparation, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

10

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

BI	US2003/0235272-A1	12-25-2003	Richard David Carr
BJ	US2004/06703238-B2	09-09-2004	Bachovchin
BK	US2004/0054171-A1	03-18-2004	Jensen et al.
BL	US2004/0058876-A1	03-25-2004	Hoffmann et al.
BM	US2004/0132732-A1	07-08-2004	Han et al.
BN	US2004/0167191-A1	08-26-2004	Demuth et al.
BO	US2004/0171555-A1	09-02-2004	Demuth et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (If Known)				
BP	FR 2,162,106 (English Abstract-1973)		11-30-1972	Amschler et al.		
BQ	WO 89/10701		11-18-1989	BASF		
BR	EP 0378255-A2		07-18-1990	Janssen Pharmaceutica		
BS	GB 2230527-A		10-24-1990	Imperial Chemical Industries Plc		
BT	WO 91/12001		08-22-1991	Merck & Co., Inc.		
BU	WO 93/21162		01-28-1993	Nissan Chemical Industries, Ltd.		
BV	WO 93/08259 (A2)		04-29-1993	New England Medical Center Hospitals, Inc.		
BW	WO 93/08259 (A3)		04-29-1993	New England Medical Center Hospitals, Inc.		
BX	EP 0547442-A1		06-23-1993	E.R. Squibb & Sons, Inc.		
BY	WO 94/03055		02-17-1994	U.S. Government, Secty, HHS		
BZ	EP 05817377-A2		03-16-1994	Eli Lilly and Company		
CA	WO 95/35031		12-28-1995	La Trobe University		
CB	WO 95/32384		10-17-1996	Telio Pharmaceutical Co., Ltd.		
CC	WO 95/38550		12-05-1996	Dana-Farber Cancer Institute, Inc.		
CD	WO 97/40832		11-06-1997	Hans-Knoll-Institut Fur Naturstoff		
CE	JP 0925977		11-18-1997	Terumo Corp.		
CF	WO 98/00439		01-08-1998	Trustees of Tufts College		
CG	WO 98/24780		06-11-1998	Amgen Inc.		
CH	WO 98/16864		04-08-1998	Point Therapeutics, Inc.		
CI	WO 99/38501		06-05-1999	Trustees of Tufts University		

Examiner Signature

Date Considered

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information required to obtain or retain a benefit by the public which is to be furnished by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C., 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

10

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

CJ	WO 99/50249	10-07-1999	Du Pont Pharmaceuticals Company		
CK	WO 99-61431	12-02-1999	Probiodrug		
CL	WO 99/67278	12-29-1999	Pro-Biodrug		
CM	WO 99/67279	12-29-1999	Pro-Biodrug		
CN	WO 00/07617	02-17-2000	Novo Nordisk		
CO	WO 00/09666	02-24-2000	U.S. Government, Secty. HHS		
CP	WO 00/15211	03-23-2000	Aksesia Pharmaceuticals, Inc.		
CQ	WO 00/76986-A1	04-11-2000	Probiodrug		
CR	WO 00/34241	06-15-2000	Novartis AG		
CS	WO 00/47219	08-17-2000	Ontogeny, Inc.		
CT	WO 00/53171	09-14-2000	Molteni L, E C, Del Fratelli Alitti Soceta' Di Esercizio S.P.A.		
CU	WO 00/57721	10-05-2000	Aksesia Pharmaceuticals, Inc.		
CV	WO 01/14318-A2	03-01-2001	Probiodrug		
CW	WO 01/34594-A1	05-17-2001	Guildford Pharmaceuticals, Inc.		
CX	WO 01/62826-A2	07-28-2001	Novartis AG		
CY	WO 01/56988-A1	08-09-2001	Kirin Beer Kabushiki Kaisha		
CZ	WO 01/07729-A1	09-27-2001	Sanofi-Synthelabo		
DA	WO 01/97806-A1	12-27-2001	Smithkline Beecham PLC		
DB	WO 02/34245-A2	05-02-2002	Probiodrug AG		
DC	WO 02/34243-A2	05-02-2002	Probiodrug AG		
DD	WO 02/083109-A1	10-24-2002	Ferring BV		
DE	JP 2002/338466	11-27-2002	Tanabe Seiyaku Co Ltd		
DF	WO 03/002593-A2	01-09-2003	Probiodrug AG		
DG	WO 03/002595-A2	01-09-2003	Probiodrug AG		
DH	WO 03/002596-A2	01-09-2003	Probiodrug AG		
DI	WO 03/016335-A2	02-27-2003	Probiodrug AG		
DJ	WO 03/022571-A2	03-20-2003	Probiodrug AG		
DK	WO 03/026562-A1	04-03-2003	Bristol-Myers Squibb Company		
DL	WO 03/030946-A1	04-17-2003	Novartis AG		
DM	WO 03/033524-A2	04-24-2003	Probiodrug AG		
DN	JP 2003/126851	05-08-2003	Sankyo Co LTD		
DO	WO 03/040174-A2	05-15-2003	Probiodrug AG		
DP	WO 03/045228-A2	06-05-2003	Trustees of Tufts College		
DQ	WO 03/045977-A2	06-05-2003	Trustees of Tufts College		
DR	WO 03/048081-A2	06-12-2003	Bristol-Myers Squibb Company		
DS	WO 03/048158-A1	06-12-2003	Bristol-Myers Squibb Company		
DT	WO 03/057200-A2	07-17-2003	Novo Nordisk		

Examiner Signature

Date Considered

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This form of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering information from the public and processing the information. This burden is not intended to reflect the average time for completing this form, including the time for review by the USPTO. The burden may vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	4	of	10	Attorney Docket Number	Complete if Known
				SYR-DPP-IV-5004-U	

DU	WO 03/063903-A2	08-07-2003	Probiotrud AG		
DV	WO 03/072555-A1	09-04-2003	Probiotrud AG		
DW	WO 03/082888-A2	10-09-2003	Probiotrud AG		
DX	WO 03/092605-A2	11-13-2003	Trustees of Tufts College		
DY	WO 03/099279-A1	12-04-2003	Novartis AG		
DZ	WO 03/099818-A1	12-04-2003	Chiron Corporation		
EA	WO 03/106416-A2	12-24-2003	Smithkline Beecham Corporation		
EB	WO 2004/017689-A1	03-04-2004	Probiotrud AG		
EC	JP 2004/096600-A	04-02-2004	Sankyo Co. Ltd.		
ED	WO 2004/031374-A2	04-15-2004	Probiotrud AG		
EE	JP 2004/123738-A	04-22-2004	Takeda Chem Ind Ltd		
EF	WO 2004/037178-A2	05-06-2004	Bristol-Myers Squibb Company		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), editor, city and/or country where published.	T ²
EG	ARGAUD, DORIANE et al.,	Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes, European J. Biochem. 213, 1341-1348 (1993).	
EH	ASHCROFT, STEPHEN J.H. et al.,	Structure-activity relationships of alloxan-like compounds derived from uric acid, Br. J. Pharmac. (1988) 89 pp. 469-472.	
EI	BAL, GUNTHER, Dipептидил Peptidase IV and Prolyl Oligopeptidase: Design, Synthesis and Evaluation of Substrates and Inhibitors. (2002) Universitа Antwerpen.		
EJ	BARAKAT, S.E.S.,	Synthesis and hypoglycemic activity of some new 3-[4-[(cyclic exylamino) carbonyl] amino]sulfonylphenyl-4(3H)-quinazolinones, Az. J. Pharm. Sci., Vol. 25, (2000) pp. 48-57.	
EK	BARAKAT, S.E.S.,	Synthesis and Hypoglycemic Activity of Some New 4(3H)-Quinazolinone Analogues, Saudi Pharmaceutical Journal, Vol. 8, No.4 (2000) pp.198-204.	
EL	BAKER, B.R. et al.,	Inreversible Enzyme Inhibitors. On the Mode of Pyrimidine Binding of 5-alkyl and 5-Arylpyrimidines to Dihydrofolic Reductase (1,2). Journal of Heterocyclic Chemistry Vol. 4 (1967) pp. 39-48.	
EM	BELGOEDERHE, ELENA et al.,	Synthesis of Substituted Pyrimidines, Study of the Structure and of the Tautomeric Equilibria, (1976) Chem. Abstracts, Columbus, OH Vol. 85 No. 9.	
EN	BEZUGLYI, P.O. et al.,	Synthesis of arylsulfonyl hydrazine of 3-R-quinazolone-4-carboxylic-2-acid, Pharmaceutical Journal (1979), pp. 70-71.	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including time for review of the information and completion of the form. Response times will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/809,635
Sheet	5	of	10
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1646
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SYR-DPP-IV-5004-U

EO	BHADURI, A.P. et al., Urinary Metabolite of 2-Piperazino-3 (H)-4-Oxiazolone (Centipiperalone), A Potent Blood Sugar Lowering Agent, Indian J. Biochem. Biophys., Vol. 12 (1975), pp. 413-414.	
EP	BOURAS, MOHAMMED, et al., Metabolism of enterostatin in rat intestine, brain, membranes and serum: differential involvement of proline-specific peptidases, Peptides, Vol. 16, No. 3, (1995), pp. 393-405.	
EQ	BRUN, JEAN-FREDERIC, et al., Effects of Oral Zinc Gluconate on Glucose Effectiveness and Insulin Sensitivity In Humans, Biological Trace Element Research Vol. 47 (1995), pp. 385-391.	
ER	BUCKLEY, DI, Analysis of the Degradation of Insulintropin [GLP-1 (7-37)] in Human Plasma and Production of Degradation Resistant Analogs.	
ES	CHATTERJEE, A.K. et al., Effect of Centipiperalone In Insulin Deficient Diabetes, Indian Journal of Experimental Biology Vol. 18 (1980), pp. 1005-1008.	
ET	CHATTERJEE, A.K. et al., Effect of Centipiperalone, a New Hypoglycemic Agent on Insulin Biosynthesis & Release from Isolated Pancreatic Islets of Rat, Indian Journal of Experimental Biology Vol. 20 (1982) pp.270-272.	
EU	COPPOLA, GARY M. et al., 1-Aminomethylisocouiline-4-carboxylates as Novel Dipeptidyl-peptidase IV Inhibitors, Biorganic & Medicinal Chemistry Letters Vol. 10 (2000), pp. 1555-1558.	
EV	DEACON, CAROLYN F. et al., Degradation of Glucagon-Like Peptide 1 <i>In Vitro</i> Yields an N-Terminally Truncated Peptide That is a Major Endogenous Metabolite <i>In Vivo</i> , Journal of Clinical Endocrinology and Metabolism Vol. 80, No. 3 (1995), pp. 952-957.	
EW	DEACON, CAROLYN F. et al., Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide 1 Are Rapidly Degraded From the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects, Diabetes, Vol. 44 (1996), pp. 1125-1131.	
EX	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Influences GLP-1 Metabolism <i>In Vivo</i> , Regulatory Peptides Vol. 64 Issues 1-3 (1996) p.30.	
EY	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Potentiates the Insulintropic Effect of Glucagon-Like Peptide 1 <i>In the Anesthetized Pig</i> , Diabetes, Vol. 47 (1998), pp. 764-769.	
EZ	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition as an Approach to the Treatment and Prevention of Type 2 Diabetes: a Historical Perspective, Biochemical and Biophysical Research Communications 294 (2002), pp. 1-4.	
FA	DEMUTH, HANS-ULRICH et al., Rebuttal to Deacon and Holst: "Metformin effects on depeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective" Biochemical and Biophysical Research Communications 298 (2002) pp. 229-232.	
FB	ENGEL, MICHAEL et al., The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functionel regulation and enzymatic mechanism, Proc. Natl. Acad. Sci. Ed. First Edition (2003), pp. 1-4.	
FC	FANTUS, I. GEORGE, et al., Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects <i>In Vitro</i> and <i>In Vivo</i> , J. Clinical Endocrinology & Metabolism (1995), pp. 890-905.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Appropriate to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to be filed (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

10

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

FD	GARRATT, PETER J. et al., A Novel Synthesis of Dihydroimidazoles, <i>J. Chem. Soc. Chem. Commun.</i> (1987), pp.569-569.	
FE	GARRATT, PETER J. et al., One-Carbon Compounds as Synthetic Intermediates. The Synthesis of Hydroimidazoles and Hydroquinazolines by Sequential Nucleophilic Addition to Diphenyl Cyanocarbonimidate With Concomitant Cyclization, <i>J. Org. Chem.</i> (1988), pp. 1062-1069.	
FF	GAZIT, AVIV et al., Tyrosostatins IV - Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4-Antidiquinazolines, <i>Bioorganic & Medicinal Chemistry</i> , Vol. 4, No.8 (1996) pp. 1203-1207.	
FG	GUERRIERI, N., et al., Vanadate Inhibition of Serine and Cysteine Proteases, <i>Comparative Biochemistry and Physiology Part A</i> 122 (1997), pp.331-338.	
FH	GUPTA, C.M. et al., Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quinazolines and Trifluoropheno- and Trifluoromethylquinazolones, Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, India (1968), pp. 392-395.	
FI	GUPTA, C.M. et al., New Potent Blood Sugar Lowering Compound, <i>Natura</i> , Vol. 223 (1969), p. 524.	
FJ	GUPTA, C.M. et al., A Novel Class of Hypoglycaemic Agents: Syntheses & SAR In 2-Substituted 4(3H)-Quinazolones, 2-Substituted 4-Hydroxypyrimidylmethene 5,6-pyrimidines & 3-Substituted 4-Oxo-pyrido [1,2-a] pyrimidines, <i>Indian Journal of Chemistry</i> , Vol. 9 (1971), pp. 201-206.	
FK	HERMECZ, ISTVAN et al., Pyrido[1,2-a]Pyrimidines; New Chemical Entities in Medicinal Chemistry, <i>Medicinal Research Reviews</i> , Vol. 6, No. 2 (1986) pp.203-230.	
FL	HINKE, SIMON A. et al., Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1, <i>Biochemical and Biophysical Research Communications</i> , 291 (2002) pp. 1302-1308.	
FM	HINKE, SIMON A. et al., On Combination Therapy of Diabetes With Metformin and Dipeptidyl Peptidase IV Inhibitors, <i>Diabetes Care</i> , Vol. 25, No. 8 (2002) pp. 1490-1492.	
FN	HOLZ, GEORGE G. et al., Pancreatic Beta-Cells are Rendered Glucose-Competent by the Insulinotropic Hormone Glucagon-Like Peptide-1 (7-37), <i>Nature</i> , Vol. 361 (1993), pp. 362-365.	
FO	KHALID, NORAINI M., et al., Purification and Partial Characterization of a Prolyl-Dipeptidyl Aminopeptidase From <i>Lactobacillus helveticus</i> CNRZ 32, <i>Applied and Environmental Microbiology</i> (1990), pp. 381-388.	
FP	KIEFFER, TIMOTHY J. et al., Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 In Vitro and In Vivo by Dipeptidyl Peptidase IV, <i>Endocrinology</i> , Vol. 136, No. 8 (1995) 3585-3596.	
FQ	KIMURA, TOSHIKIRO et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats, <i>Biological & Pharmaceutical Bulletin</i> , Vol. 19, No. 6 (1996) 697-900.	
FR	KOREEDA, YUJI et al., Isolation and Characterization of Dipeptidyl Peptidase IV From <i>Prevotella ikeschii</i> ATCC 15930, <i>Archives of Oral Biology</i> , 46 (2001), 759-766.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 A reference is considered unique if it contains a unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required under 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Collection of information is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the information. (This estimate does not include time for reviewing the information by the USPTO.) This burden, depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

10

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

FS	KUSAR, MIHAEL et al., Diethyl N,N-Dimethylaminomethylenemalonate in the Synthesis of Fused Heterocyclic Systems, <i>Heterocyclic Chem.</i> 33 (1995) pp. 1041-1046.	
FT	LI JINPING, et al., Pernmyoate and Pertungstate—Potent Stimulators of Insulin Effects in Rat Adipocytes: Mechanism of Action, <i>Biochemistry</i> , 34 (1995) 6219-6225.	
FU	LIN, JIAN, Total Synthesis and Biological Evaluation of Fluoroacillin-containing Dipeptidyl Iactamase as Inhibitors of Dipeptidyl Peptidase IV (CD26), Dissertation presented to State University of New York at Albany, Department of Chemistry (1998).	
FV	LOESE, ERIC et al., Selective N-Alkylation of Primary Amines with Chloroacetamides Under pH-Controlled Aqueous Conditions, <i>Synthetic Communications</i> , 32(3) (2002) pp. 403-409.	
FW	MANNUCCI, EDUARDO, et al., Effect of Metformin on Glucagon-Like Peptide-1 (GLP-1) and Leptin Levels in Obese Nonobese Subjects, <i>Diabetes Care</i> , Vol. 24, No. 3 (2001) 489-494.	
FX	MENTLEIN, ROLF et al., Dipeptidyl-Peptidase IV Hydrolyses gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1-(7-36)amide, Peptide Histidine Methionine and Is Responsible for Their Degradation in Human Serum, <i>Eur. J. Biochem.</i> , Vol. 214, 829-835 (1991).	
FY	MEYEROWITCH, JOSEPH et al., Oral Administration of Vanadate Normalizes Blood Glucose Levels in Streptozotocin-Treated Rats, <i>The Journal of Biological Chemistry</i> , Vol. 262, No. 14 (1987) 6658-6662.	
FZ	MALLOY, J. ARDILL et al., Effect of Metformin Treatment on Gastric Acid Secretion Gastrointestinal Hormone Levels in Normal Subjects, <i>Diabetologia</i> , Vol. 19 (1980) 93-96.	
GA	MUKERJEE, S.S. et al., Effect of 2-piperazine-4(3H)-quinoxalinone monoacetate on the tissue respiration, glucose uptake and lactate production by rat hemidiaphragm, <i>Biochemical Pharmacology</i> , Vol. 23 (1974) 3068-3067.	
GB	MUKERJEE, S.S. et al., Studies on the Mechanism of Centipiperalone-Induced Hypoglycemia, <i>Acta Diabet. Lat</i> 13, 8 (1976) p. 8.	
GC	MUKERJEE, S.S. et al., Chronic Toxicity Studies of a Hypoglycemic Compound: Centipiperalone in Rats & Rhesus Monkeys, <i>Indian Journal of Experimental Biology</i> , Vol. 17 (1979) pp. 1348-1349.	
GD	MUKHERJEE, S.S. et al., Tissue Distribution of [³ H]Centipiperalone after Oral Administration, <i>Indian J. Biochem. Biophys.</i> , Vol. 17 (1980) pp. 399-401.	
GE	MUKHERJEE, SURATH K. et al., A novel hypoglycemic compound, <i>Biochemical Pharmacology</i> , Vol. 22 (1972) pp. 1529-1531.	
GF	MUKHERJEE, SURATH K. et al., Effect of 2-piperazine-4(3H)-quinoxalinone monoacetate on some aspects of carbohydrate metabolism of albino rats, <i>Biochemical Pharmacology</i> , Vol. 22 (1973) pp. 2205-2206.	
GG	MUKHERJEE, SURATH K. et al., Studies on the Metabolic Changes Induced by a Synthetic Insulinogenic Agent, <i>Ind. J. Physiol. & Allied Sci.</i> , Vol. 30, No. 3 (1976) pp. 105-116.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

10

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

GH	MUKHERJEE, SURATH K. et al., Influence of Timing Oral Dosing of a Novel Hypoglycaemic Agent A-4166 In Relation to Food, Diabetologia Vol. 38 A164 Supplement 1 (1995).	
GI	MUKHERJEE, Subal S. et al., Studies on the Mechanism of Centipiperalone-Induced Hypoglycemia, Acta Diabet. Lat. 13, 8, (1976) pp. 8-19.	
GJ	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Part V - Synthesis & Hypoglycemic Activity of Some New 1-[D-(4-Oxo-2-MethylPhenyl-3 (4H)-Quinazolinyl) Phenyl] 3-Aryl-2-Ureas, Indian Drugs, 25 (1) (1987) pp. 19-22.	
GK	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Synthesis and Hypoglycemic Activity of Some New 1-[D-(4-Oxo-2-Substituted-3-(4H)-Quinazolinyl)-Phenyl] Sulphonyl-3-Aryl/Cyclohexyl-2-Thioureas, Current Science, Vol. 55, No. 24 (1987) pp. 1263-1265.	
GL	NAKAMURA, SEIJI, et al., Effect of Chronic Venarate Administration in Partially Depancreasitized Rats, Diabetes Research and Clinical Practice 27 (1995) pp. 51-59. (Abstract Only)	
GM	OKIKUBO, I. et al., Dipeptidyl Peptidase IV From Porcine Seminal Plasma: Purification, Characterization, and N-Terminal Amino Acid Sequence, J. Biochem. (Tokyo) (1994) 116(6) pp. 1182-1182.	
GN	PANDEYA, S.N. et al., Synthesis of Some New Amidine Derivatives As Potent Hypoglycemic Agents, Pharmacological Research Communications, Vol. 17, No.8 (1985) pp. 699-709.	
GO	PAULY, R.P. et al., Inhibition of Dipeptidyl Peptidase IV (DPIV) in Rat Results in Improved Glucose Tolerance, Regulatory Peptides Vol. 64, Issues 1-3 (1998) p. 148.	
GP	PEDERSON, RAYMOND A. et al., Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide, Diabetes, Vol. 47 (1998) pp. 1253-1258.	
GQ	PILLAI, SREEKUMAR et al., Effects of ATP, Vanadate, and Molybdate on Cathepsin D-catalyzed Proteolysis, The Journal of Biological Chemistry, Vol. 260, No. 14 (1985) pp. 8384-9.	
GR	PODANYI, BENJAMIN et al., Nitrogen Bridgehead Compounds. 62. Conformational Analysis of 6, 7, 8, 9-Tetrahydro-4H-pyridol[1,2-a]pyrimidin-4-ones and Their Methyl Derivatives by NMR Spectroscopy, J. Org. Chem. 51 (1985) 394-399.	
GS	POJE, M. et al., Diabetogenic action of alizaran-like derivatives of uric acid, Experientia 36 (1980) pp. 78-9.	
GT	POJE, M. et al., Oxidation of Uric Acid. 4. Synthesis, Structure, and Diabetogenic Action of 5-Imino-2,4,6-(H,3H,5H)-pyrimidinetrone Salts and Their Alloxan-like Covalent Adducts, J. Med. Chem. 26 (1983) 861-4.	
GU	POLACEK, I. et al., Hypoglycemic Activity of Amine Derivatives, Arzneim.-Forsch./Drug Res. 28 (1978), 701-83.	
GV	PRIDAL, L. et al., Glucagon-Like Peptide-1(7-37) Has a Larger Volume of Distribution Than Glucagon-Like Peptide(1-7-36)amide in Dogs and is Degraded More Quickly In Vitro by Dog Plasma, European Journal of Drug Metabolism and Pharmacokinetics, Vol. 21 (1995), pp. 51-59.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's or inventor's citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.96. The information is being collected to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9

of 10

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

GW	RAM, VISHNU JI et al., Synthesis and Antihyperglycemic Activity of Suitably Functionalized 3H-quinazolin-4-ones, <i>Bioorganic & Medicinal Chemistry</i> 11 (2003), pp. 2439-2444.
GX	SAWYER, JAMES H. et al., Pyrido[1,2-a]pyrimidinium Salts. Part 1. Synthesis from 2-Aminopyridines and Interconversion with 2-(2-Acetylaminylamino) pyridines, <i>J.C.S. Perkin I</i> (1972), 1138-1143.
GY	SAXENA, A.M. et al., Mode of action of three structurally different hypoglycemic agents: A comparative study, <i>Indian Journal of Experimental Biology</i> , Vol. 34 (1996), pp. 351-355.
GZ	SEDO, ALEKSI et al., Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? <i>Biochimica et Biophysica Acta</i> 1550 (2001), pp. 107-116.
HA	SEKIYA, T. et al., Pyrimidine derivatives. III (1) Synthesis of hypoglycemic 4-alkoxy-2-piperazino-activity of 6-methylpyrimidinylamines, <i>Eur. J. Med. Chem.</i> (1982), 75-79.
HB	SENTEN, KRISTEL et al., Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors, <i>Bioorganic & Medicinal Chemistry Letters</i> 12 (2002) pp. 2825-2828.
HC	SETH, M. et al., Syntheses of 2-Substituted & 2,3-Distributed 4(3H)-Quinazolones, <i>Indian Journal of Chemistry</i> , Vol. 14B (1975), 538-540.
HD	SHIMAZAWA, RUMIKO et al., Novel Small Molecule Nonapeptide Aminopeptidase N Inhibitors with A Cyclic Imide Skeleton, <i>J. Enzyme Inhibition</i> , Vol. 14 (1999) pp. 259-275.
HE	SHISHHEVA, ASSIA, et al., Insulinlike Effects of Zinc Ion In Vitro and In Vivo; Preferential Effects on Desensitized Adipocytes and Induction of Normoglycemia in Streptozocin-Induced Rats, <i>Diabetes</i> , Vol. 41 (1992), pp. 982-988.
HF	SINYAK, R. S. et al., Synthesis and Biological Properties of Derivatives of 4-Hetarylmercaptoquinazoline, Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 20, No. 2, pp 168-171 (1986), pp. 103-105.
HG	SOKAL, JOSEPH E., Basal Plasma Glucagon Levels of Man, <i>Journal of Clinical Investigation</i> , Vol. 46, No.5 (1987) pp. 778-785.
HH	SIRIVASTAVA, P.P. et al., Efficacy of Centipiperazine in Combination With Biguanide & Sulfonylurea, <i>Indian Journal of Experimental Biology</i> , Vol. 21 (1983), pp. 390-392.
HI	TANAKA, KEIJU et al., Varatardine Inhibits the ATP-Dependant Degradation of Proteins In Reticulocytes Without Affecting Ubiquitin Conjugation, <i>The Journal of Biological Chemistry</i> , Vol. 258, No. 4 (1983), 2803-2809.
HJ	VILLHAUER, EDWIN B. et al., DPP-IV Inhibition and Therapeutic Potential, <i>Annual Reports in Chemistry</i> 36 (2001), 191-200.
HK	VILLHAUER, EDWIN B. et al., 1-[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, <i>J. Med. Chem.</i> 46 (2003), pp. 2774-2785.

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.68. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/809,635	
Sheet	10	of	10	Filing Date	March 24, 2004
				First Named Inventor	Jun Feng
				Group Art Unit	1646
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	SYR-DPP-IV-5004-U

HL	WELLS, CAROL L. et al., Role of Anaerobic Flora in the Translocation of Aerobic and Facultatively Anaerobic Intestinal Bacteria, Infection and Immunity, Vol. 55, No. 11 (1987) pp. 2889-94.	
HM	WIEDEMAN, PAUL E. et al., Dipeptidyl peptidase IV Inhibition for the treatment of Impaired glucose tolerance and type 2 diabetes, Current Opinion In Investigational Drugs, Vol. 4, No. 4 (2003), pp. 412-420.	
HN	YASUDA, NOBUYUKI et al. Enhanced Secretion of Glucagon-Like Peptide 1 by Biguanide Compounds, Biochemical and Biophysical Research Communications 298 (2002), pp. 779-784.	
HO	YUEN, V.G. et al., Acute and Chronic Oral Administration of Bis(maltolato)oxovanadium(IV) in Zucker Diabetic Fatty (ZDF) Rat, Diabetes Research and Clinical Practice 43 (1999), pp. 9-19.	
HP	ZANDER, METTE, et al., Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin In Type 2 Diabetes, Diabetes Care, Vol. 24, No. 4 (2001) pp. 720-725.	
HQ	ZHANG, ANQI et al., Vanadate Stimulation of Insulin Release in Normal Mouse Islets, The Journal of Biological Chemistry, Vol. 266, No. 32 (1991), pp. 21649-55.	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Application Filing Identification number (optional). 2 Applicant is to place a check-mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Confidentiality is governed by 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This burden will be directly borne by the individual. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 14

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number Number & Kind Code* (If known)	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA	US 3,980,049		6/1/1978	Ahrens, Hanns et al.	
AB	US 4,494,978		1/22/1985	Chan, David C. K.	
AC	US 4,935,493		6/19/1990	Bachovchin, William W. et al.	
AD	US 5,366,882		11/22/1994	Venton, Duane L. et al.	
AE	US 5,387,512		2/27/1995	Balan, Suresh K. et al.	
AF	US 5,433,965		7/18/1995	Bredenhorst, Reinhard et al.	
AG	US 5,462,928		10/31/1995	Bachovchin, William W. et al.	
AH	US 5,543,398		8/6/1996	Powers, James C. et al.	
AI	US 5,601,988		2/1/1997	Takacs, Laszlo	
AJ	US 5,614,379		3/25/1997	Mackellar, Warren C.	
AK	US 5,624,894		4/29/1997	Bodor, Nicholas S.	
AL	US 5,811,278		9/22/1998	Okamura, Hidetaka et al.	
AM	US 5,811,281		9/22/1998	Quanlon, Andrea et al.	
AN	US 5,814,480		9/29/1998	Venton, Duane L. et al.	
AO	US 5,865,997		3/23/1999	Lohray, Vidya Bhushan et al.	
AP	US 5,939,560		8/17/1999	Jenkins, Paul D. et al.	
AQ	US 5,965,532		10/12/1999	Bachovchin, William W.	
AR	US 5,985,884		11/16/1999	Lohray, Vidya Bhushan et al.	
AS	US 6,006,753		12/28/1999	Efendic, Suaad	
AT	US 6,011,155		1/4/2000	Villhauer, Edwin Bernard	
AU	US 6,090,786		7/18/2000	Augustyns, Koen Jan Ludovicus et al.	
AV	US 6,107,317		8/22/2000	Villhauer, Edwin Bernard	
AW	US 6,110,949		8/29/2000	Villhauer, Edwin Bernard	
AX	US 6,124,305		9/26/2000	Villhauer, Edwin Bernard	
AY	US 6,129,911		10/10/2000	Farts, Ronald A.	
AZ	US 2001/0018210		8/30/2001	Bachovchin, William et al.	
BA	US 2001/0031780		10/18/2001	Kanstrup, Anders et al.	
BB	US 2001/0047078		11/29/2001	Chang, Yie-Hwa	
BC	US 6,172,081		1/9/2001	Damon, Robert	
BD	US 6,184,020		2/6/2001	Blinkovskiy, Alexander et al.	
BE	US 6,201,132		3/13/2001	Jenkins, Paul D. et al.	
BF	US 6,214,340		4/10/2001	Takouchi, Tomio et al.	
BG	US 6,235,493		5/22/2001	Bissell, Eugene R. et al.	
BH	US 6,251,391		6/26/2001	Wilkinson, Randell Eugene et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file or by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of 14

Complete if Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte

Attorney Docket Number

SYR-DPP-IV-5004-U

BI	US 6,261,794	7/17/2001	Chang, Yie-Hwa
BJ	US 6,265,551	7/24/2001	Duke-Cohen, Jonathan S. et al.
BK	US 6,308,868	10/30/2001	Monod, Michel
BL	US 6,310,069	10/30/2001	Lohray, Vidya Bhushan et al.
BM	US 6,325,989	12/4/2001	Duke-Cohen, Jonathan S. et al.
BN	US 2002/0006899	1/17/2002	Pospisil, Andrew J. et al.
BO	US 2002/0019411	2/14/2002	Robt, Jeffrey A. et al.
BP	US 2002/0037829	3/28/2002	Arnonson, Peter S. et al.
BQ	US 2002/0041871	4/11/2002	Brudnak, Mark A.
BR	US 2002/0061839	5/23/2002	Scharpe, Simon Lodewijk et al.
BS	US 2002/0071838	6/13/2002	Demuth, Hans-Ulrich et al.
BT	US 2002/0077340	6/20/2002	Sulsky, Richard et al.
BU	US 2002/0082292	6/27/2002	Sahoo, Soumya P. et al.
BV	US 2002/0103342	8/1/2002	Sahoo, Soumya P. et al.
BW	US 2002/0103384	8/1/2002	Karstrup, Anders et al.
BX	US 2002/0110560	8/15/2002	Demuth, Hans-Ulrich et al.
BY	US 2002/0115843	8/22/2002	Oi, Steve et al.
BZ	US 2002/0132979	9/19/2002	Chen, Wen-Tien
CA	US 2002/0147130	10/10/2002	Huber, Brigitte T. et al.
CB	US 2002/0147157	10/10/2002	Connor, Gregory S.
CC	US 2002/0155565	10/24/2002	Garin-Chesa, Pilar et al.
CD	US 2002/016100	02/07/2002	Okabe, Toshiaki et al.
CE	US 2002/0164759	11/7/2002	Travis, James et al.
CF	US 2002/0165184	11/7/2002	Demuth, Hans-Ulrich et al.
CG	US 2002/0165337	12/5/2002	Suleky, Richard B. et al.
CH	US 2002/0163390	12/19/2002	Villhauer, Edwin Bernard
CI	US 2002/0168205	12/26/2002	Himmerlebäck, Frank et al.
CJ	US 6,335,429	1/1/2002	Cai, Sui Xiong et al.
CK	US 6,337,069	1/8/2002	Grouzmman, Eric et al.
CL	US 6,342,611	1/29/2002	Weber, Eckard et al.
CM	US 6,355,814	3/12/2002	Walther, Barbara P
CN	US 6,395,767	5/28/2002	Robt, Jeffrey A. et al.
CO	US 6,432,969	6/13/2002	Villhauer, Edwin Bernard
CP	US 6,447,772	9/10/2002	Houston, Devin B.
CQ	US 6,458,924	10/1/2002	Knudsen, Liselotte Bjerre et al.
CR	US 6,485,955	11/26/2002	Huber, Brigitte T. et al.
CS	US 6,495,544	12/17/2002	Hansen, Jr., Donald W. et al.
CT	US 2003/0006905	1/9/2003	Demuth, Hans-Ulrich et al.

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Application unique identifier designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 14

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

CU	US 2003/0027282	2/6/2003	Huber, Brigitte T. et al.
CV	US 2003/0040478	2/27/2003	Drucker, Daniel J. et al.
CW	US 2003/0045464	3/6/2003	Henneberg, Ronald Norbert et al.
CX	US 2003/0055052	3/23/2003	Peters, Stefan et al.
CY	US 2003/0060412	3/27/2003	Prouty, Walter Francis et al.
CZ	US 2003/0060434	3/27/2003	Nielesen, Loretta et al.
DA	US 2003/0067935	5/6/2003	Cheng, Peter T. et al.
DB	US 2003/0087950	5/6/2003	DeNantouil, Guillaume et al.
DC	US 2003/0089935	5/15/2003	Fan, Tsao-Hung et al.
DD	US 2003/0092697	5/15/2003	Cheng, Peter T. et al.
DE	US 2003/0096846	5/22/2003	Cheng, Peter T. et al.
DF	US 2003/0096857	5/22/2003	Evans, David Michael et al.
DG	US 2003/0100563	5/23/2003	Edmondson, Scott D. et al.
DH	US 2003/0103968	6/5/2003	Amelsberg, Andree et al.
DI	US 2003/0105077	6/5/2003	Kanstrup, Anders Bendtz et al.
DJ	US 2003/0119738	6/26/2003	Demuth, Hans-Ulrich et al.
DK	US 2003/0119738	6/26/2003	Niestroj, Andre et al.
DL	US 2003/0125304	7/3/2003	Demuth, Hans-Ulrich et al.
DM	US 2003/0130281	7/10/2003	Boehringer, Markus et al.
DN	US 2003/0130306	7/10/2003	Devashah, Pratik et al.
DO	US 2003/0139429	7/24/2003	Cohen, David Saul et al.
DP	US 2003/0139434	7/24/2003	Balkan, Bork et al.
DQ	US 2003/0144206	7/31/2003	Knudsen, Lotte Bjerre et al.
DR	US 2003/0149071	8/7/2003	Gobbi, Luca Claudio et al.
DS	US 2003/0166662	9/4/2003	Fryburg, David Albert et al.
DT	US 2003/0166690	9/4/2003	Ebdrup, Soren et al.
DU	US 2003/0171358	9/11/2003	Jeppeesen, Lone et al.
DV	US 2003/0171411	9/11/2003	Kodra, Janos Tibor et al.
DW	US 2003/0181497	9/23/2003	Chen, Ping et al.
DX	US 2003/0186963	10/2/2003	Donwald, Florencio Zaragoza et al.
DY	US 2003/0187254	10/2/2003	Perry, David A. et al.
DZ	US 2003/0191112	10/5/2003	Donwald, Florencio Zaragoza et al.
EA	US 2003/0195188	10/16/2003	Boehringer, Markus et al.
EB	US 2003/0195190	10/16/2003	Peschke, Bernd et al.
EC	US 2003/0199528	10/23/2003	Kanstrup, Anders B. et al.
ED	US 2003/0199563	10/23/2003	Robi, Jeffrey A. et al.
EE	US 2003/0203946	10/30/2003	Behrens, Consten et al.
EF	US 2003/0216382	11/20/2003	Boehringer, Markus et al.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 14

Complete If Known

Application Number	10/809,835
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

EG	US 2003/0216450	11/20/2003	Evans, David Michael et al.
EH	US 2003/0220345	11/27/2003	Hamby, James Marino et al.
EI	US 2003/0225102	12/4/2003	Sankaranarayanan, Alangudi
EJ	US 2003/0232761	12/18/2003	Hinkin, Simon A. et al.
EK	US 6,521,644	2/18/2003	Broqua, Pierre
EL	US 6,526,486	3/4/2003	Larsen, Bjarne Due et al.
EM	US 6,545,170	4/8/2003	Pitzle, Bennett S et al.
EN	US 6,548,529	4/16/2003	Robb, Jeffrey A. et al.
EO	US 6,555,519	4/23/2003	Washburn, William N.
EP	US 6,555,521	4/23/2003	Hemmeling, Ronald Norbert et al.
EQ	US 6,559,186	5/6/2003	Gatlin, Marjorie Regan et al.
ER	US 6,573,096	6/3/2003	Chen, Wen-Tien
ES	US 6,573,287	6/3/2003	Sulsky, Richard B. et al.
ET	US 6,586,196	7/1/2003	Brown, Nancy J.
EU	US 6,606,038	8/19/2003	Caplan, Shari L. et al.
EV	US 6,617,340	9/9/2003	Villhauer, Edwin Bernard
EW	US 6,620,821	9/16/2003	Robb, Jeffrey A.
EX	US 6,627,638	9/30/2003	Robb, Jeffrey A.
EY	US 6,645,995	11/11/2003	Kanstrup, Anders et al.
EZ	US2004/0002495	1/1/2004	Sher, Philip et al.
FA	US2004/0002609	1/1/2004	Hulin, Bernard
FB	US2004/0006062	1/8/2004	Smalheer, Joanne M. et al.
FC	US2004/0009972	1/15/2004	Ding, Charles Z. et al.
FD	US2004/0009996	1/15/2004	Dhar, T. G. Murali et al.
FE	US2004/0034014	2/19/2004	Kanstrup, Anders Bendtz et al.
FF	US2004/0053369	3/16/2004	Abbott, Catherine Anne et al.
FG	US2004/0063935	4/1/2004	Yasuda, Kosuke
FH	US2004/0072874	4/15/2004	Sato, Nagao et al.
FI	US2004/0072892	4/15/2004	Fukuhima, Hiroshi et al.
FJ	US2004/0077645	4/22/2004	Himmelsbach, Frank et al.
FK	US2004/0082497	4/29/2004	Evans, David Michael et al.
FL	US2004/0082607	6/4/2004	Oli, Saton et al.
FM	US2004/0087587	5/6/2004	Himmelsbach, Frank et al.
FN	US2004/0092478	5/13/2004	Rothermel, John D. et al.
FO	US2004/0097510	5/20/2004	Himmelsbach, Frank et al.
FP	US2004/0106655	6/3/2004	Kitajima, Hiroshi et al.
FQ	US2004/0106656	6/3/2004	Ashton, Wallace T. et al.
FR	US2004/0106802	6/3/2004	Sankaranarayanan, Alangudi et al.

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to be furnished by the USPTO (process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
				Application Number	10/809,635
				Filing Date	March 24, 2004
				First Named Inventor	Jun FENG
				Group Art Unit	1624
				Examiner Name	Kahsay Habte
Sheet	5	of	14	Attorney Docket Number	SYR-DPP-IV-5004-U

FS	US2004/0110817	8/10/2004	Hulin, Bernard	
FT	US2004/0116326	8/17/2004	Yoshikawa, Seiji et al.	
FU	US2004/0132713	7/8/2004	Hulin, Bernard et al.	
FV	US2004/0136148	7/19/2004	Fushimi, Nobuhiko et al.	
FW	US2004/0136214	7/15/2004	Himmlerbach, Frank et al.	
FX	US2004/0138215	7/15/2004	Eckhard, Matthias et al.	
FY	US2004/0147434	7/23/2004	Ansege, Siegfried et al.	
FZ	US2004/0162122	8/5/2004	Bachovchin, William et al.	
GA	US2004/0152745	8/5/2004	Jackson, Paul et al.	
GB	US2004/0166125	8/26/2004	Himmlerbach, Frank et al.	
GC	US2004/0167133	8/26/2004	Edmondson, Scott D. et al.	
GD	US2004/0167341	8/26/2004	Haffner, Curt Dale et al.	
GE	US2004/0171104	9/2/2004	Blinkovsky, Alexander et al.	
GF	US2004/0171848	9/2/2004	Haffner, Curt Dale et al.	
GG	US2004/0176408	9/9/2004	Gobbi, Luca Claudio et al.	
GH	US2004/0176426	9/9/2004	Edmondson, Scott D et al.	
GI	US2004/0180925	9/16/2004	Matsuno, Kenji et al.	
GJ	US2004/0186163	9/23/2004	Yasuda, Nobuyuki et al.	
GK	US2004/0198786	10/7/2004	Gretzke, Dirk et al.	
GL	US2004/0209891	10/21/2004	Broqua, Pierre et al.	
GM	US2004/0229820	11/18/2004	Bachovchin, William W. et al.	
GN	US2004/0229848	11/18/2004	Demuth, Hans-Ulrich et al.	
GO	US2004/0236102	11/25/2004	Brockmiller, Linda et al.	
GP	US2004/0242566	12/2/2004	Feng, Jun et al.	
GQ	US2004/0242568	12/2/2004	Feng, Jun et al.	
GR	US2004/0242636	12/2/2004	Haffner, Curt Dale et al.	
GS	US2004/0242898	12/2/2004	Hulin, Bernard et al.	
GT	US2004/0254167	12/16/2004	Bitlu, Tesfaye et al.	
GU	US2004/0254226	12/16/2004	Feng, Jun et al	
GV	US2004/0259843	12/23/2004	Macias, David J. et al.	
GW	US2004/0259870	12/23/2004	Feng, Jun et al.	
GX	US2004/0259883	12/23/2004	Sakashita, Hiroshi et al.	
GY	US2004/0259902	12/23/2004	Boehringer, Markus et al.	
GZ	US2004/0259903	12/23/2004	Boehringer, Markus et al.	
RA	US2004/0259919	12/23/2004	Magrin, David R. et al.	
HB	US 6,673,815	1/6/2004	Devasthale, Pratik et al.	
HC	US 6,673,829	1/6/2004	Dowwald, Florencio Zaragoza et al.	
HD	US 6,686,337	2/3/2004	Connor, Gregory S.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of reference with next communication to applicant.

1. Applicant's name and citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit which the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			<i>Complete If Known</i>		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/809,635	
Sheet	6	of	14	Filing Date	March 24, 2004
				First Named Inventor	Jun FENG
				Group Art Unit	1624
				Examiner Name	Kahsay Habte
				Attorney Docket Number	SYR-DPP-IV-5004-U

HE	US 6,699,671	3/2/2004	Edmondson, Scott D. et al.
HF	US 6,706,742	3/16/2004	De Nanteuil, Guillaume et al.
HG	US 6,710,040	3/23/2004	Huin, Bernard et al.
HH	US 6,716,843	4/6/2004	De Nanteuil, Guillaume et al.
HI	US 6,727,261	4/27/2004	Gobbi, Luca Claudio et al.
HJ	US 6,727,271	4/27/2004	Cheng, Peter T. et al.
HK	US 6,800,650	10/5/2004	Boehringer, Markus et al.
HL	US 6,803,357	10/12/2004	Bachovchin, William A. et al.
HM	US 6,825,169	11/30/2004	Bachovchin, William W. et al.
HN	US20050104732	1/20/2005	Gulve, Eric Arthur et al.
HO	US20050104946	1/20/2005	Demuth, Hans-Ulrich et al.
HP	US200501020574	1/27/2005	Haesel, Norbert et al.
HQ	US20050026921	2/3/2005	Eckhardt, Matthias et al.
HR	US20050032804	2/10/2005	Cypes, Stephen Howard et al.
HS	US20050036200	2/17/2005	Hannemann, Lawrence G. et al.
HT	US20050043292	2/24/2005	Parker, Janice C. et al.
HU	US20050043299	2/24/2005	Evans, David M. et al.
HV	US20050056335	3/17/2005	Demuth, Hans-Ulrich et al.
HW	US 6,861,440	3/1/2005	Boehringer, Markus et al.
HX	US 6,867,205	3/15/2005	Boehringer, Markus et al.

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
HY	DE 2381551A1	6/19/1975	BASF AG			
HZ	DE 2500024A1	7/8/1976	BASF AG,			
IA	EP 0505893	9/30/1992	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG			
IB	EP 0547514	6/23/1993	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG			
IC	EP 0574846	12/22/1993	MERCK PATENT GmbH			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449a/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Sheet	7	of	14
Complete If Known			
Application Number		10/809,635	
Filing Date		March 24, 2004	
First Named Inventor		Jun FENG	
Group Art Unit		1624	
Examiner Name		Kahsay Habte	
Attorney Docket Number		SYR-DPP-IV-5004-U	

	ID	EP 0657452	6/14/1995	MERCK PATENT GmbH		
	IE	EP 0702013	3/20/1996	MERCK PATENT GmbH		
	IF	GB 1441665A	7/7/1978	COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION		
	IG	WO 91/11457	8/8/1991	BUCKLEY, Douglas, I. Et al.		
	IH	WO 95/15309	6/8/1995	FERRING B.V.		
	II	WO 95/29691	11/9/1995	GEORGIA TECH RESEARCH CORPORATION		
	IJ	WO 96/02867	2/1/1996	AMGEN INC.		
	IK	WO 98/16763	5/7/1998	TANABE SEIYAKU CO., LTD.		
	IL	WO 98/19996	5/14/1998	NOVARTIS AG		
	IM	WO 98/50046	11/12/1998	TRUSTEES OF TUFTS COLLEGE		
	IN	WO 98/51603	11/19/1998	NOVO NORDISK BIOTECH, INC.		
	IO	WO 99/02705	1/21/1999	SOCIETE DES PRODUITS NESTLE S.A.		
	IP	WO 99/17799	4/15/1999	TRUSTEES OF TUFTS COLLEGE ET AL		
	IQ	WO 99/18856	4/22/1999	CYTOTOX, INC.		
	IR	WO 99/28474	6/10/1999	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES		
	IS	WO 99/46272	9/16/1999	FONDATECH BENELUX N.V.		
	IT	WO 99/47152	9/23/1999	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH		
	IU	WO 99/62914	12/9/1999	POINT THERAPEUTICS, INC.		
	IV	WO 00/10549	3/2/2000	POINT THERAPEUTICS, INC.		
	IW	WO 00/20416	4/13/2000	GANTE, Helga		
	IX	WO 00/40583	7/13/2000	MERCK PATENT GMBH		
	IY	WO 00/43366	7/27/2000	KIRIN BEER KABUSHIKI KAISHA		
	IZ	WO 00/56296	9/28/2000	FERRING B.V.		
	JA	WO 00/56297	9/28/2000	FERRING B.V.		
	JB	WO 01/16301	3/8/2001	TUFTS UNIVERSITY		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to please check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

14

Complete if Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

JC	WO 01/19866	3/22/2001	THE UNIVERSITY OF SYDNEY		
JD	WO 01/40180	6/7/2001	FERRING BV		
JE	WO 01/55105	8/2/2001	NOVO NORDISK A/S		
JF	WO 01/62266	8/30/2001	NOVO NORDISK A/S		
JG	WO 01/68603	9/20/2001	BRISTOL-MYERS SQUIBB CO.		
JH	WO 01/72290	10/4/2001	PROBIODRUG GESELLSCHAFT FÜR ARZNEIMITTELFORSCHUNG MBH		
JI	WO 01/74299	10/11/2001	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK		
JJ	WO 01/79206	10/25/2001	SUMITOMO PHARMACEUTICALS COMPANY, LIMITED		
JK	WO 01/81304	11/1/2001	FERRING BV		
JL	WO 01/81337	11/1/2001	FERRING B.V.		
JM	WO 01/89569	11/23/2001	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH (IMTM		
JN	WO 01/94587	12/13/2001	PROZIMEX A/S		
JO	WO 02/04610	1/17/2002	BAYER AKTIENGESELLSCHAFT		
JP	WO 02/051836	7/4/2002	KYOWA HAKKO KOGYO CO., LTD		
JQ	WO 02/053170	7/11/2002	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH (IMTM		
JR	WO 02/059301	8/1/2002	K.U. LEUVEN RESEARCH AND DEVELOPMENT		
JS	WO 02/059343	8/1/2002	VANDERBILT UNIVERSITY		
JT	WO 02/062764	8/15/2002	TAKEDA CHEMICAL INDUSTRIES, LTD.		
JU	WO 02/066627	8/29/2002	BAYER AKTIENGESELLSCHAFT		
JV	WO 02/068420	9/9/2002	BOEHRINGER INGELHEIM PHARMA KG		
JW	WO 02/076450	10/3/2002	MERCK & CO., INC.		
JX	WO 02/083128	10/24/2002	BRISTOL-MYERS SQUIBB COMPANY		
JY	WO 02/08931	1/31/2002	TEN SQUARE		
JZ	WO 02/092127	11/21/2002	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM		
KA	WO 02/096357	12/5/2002	BRISTOL-MYERS SQUIBB COMPANY		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

1 Applicant's or patentee's obligation to furnish information under 37 CFR 1.36. To place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to be furnished by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

9

of

14

Complete if Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

KB	WO 02/14271	2/21/2002	WELFIDE CORPORATION		
KC	WO 02/20804	3/14/2002	PROZYMEX A/S		
KD	WO 02/26703	4/4/2002	PROLIFIX LIMITED		
KE	WO 02/28742	4/11/2002	JOHANSSON, Thomas		
KF	WO 02/30890	4/18/2002	TANABE SEIYAKU CO., LTD.		
KG	WO 02/30891	4/18/2002	TANABE SEIYAKU CO., LTD.		
KH	WO 02/31134	4/18/2002	FERRING BV		
KI	WO 02/34900	5/2/2002	THE UNIVERSITY OF SYDNEY		
KJ	WO 02/38541	5/16/2002	TAISHO PHARMACEUTICAL CO., LTD.		
KK	WO 02/38742	5/16/2002	THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.		
KL	WO 03/000180	1/3/2003	MERCK & CO., INC.		
KM	WO 03/000250	1/3/2003	FERRING BV		
KN	WO 03/002530	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
KO	WO 03/002531	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
KP	WO 03/002553	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
KQ	WO 03/004496	1/16/2003	NOVO NORDISK A/S		
KR	WO 03/004498	1/16/2003	MERCK & CO., INC.		
KS	WO 03/010197	2/6/2003	GENSET S.A.		
KT	WO 03/010314	2/6/2003	GENSET S.A.		
KU	WO 03/011807	2/13/2003	NOVO NORDISK A/S		
KV	WO 03/011814	2/13/2003	NOVO NORDISK A/S		
KW	WO 03/011834	2/13/2003	NOVO NORDISK A/S		
KX	WO 03/011882	2/13/2003	THE U.S. GOVERNMENT as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
KY	WO 03/014318	2/20/2003	GENZYME CORPORATION		
KZ	WO 03/015775	2/27/2003	PROBIODRUG AG		
LA	WO 03/017936	3/6/2003	YALE UNIVERSITY		
LB	WO 03/024942	3/27/2003	MITSUBISHI PHARMA CORPORATION		

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Insert copy of this form with next communication to applicant. If English language Translation is attached, check mark here. If English language Translation is not attached, check mark here. If English language Translation is attached, check mark here.

1 A complete foreign language disclosure statement (for example, 2 pages) must be placed in the application if English language Translation is attached. This collection of information is required by 37 CFR 1.68. The information is required to obtain or retain a benefit which is to file the application (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/809,635	
Sheet	10	of	14	Filing Date	March 24, 2004
				First Named Inventor	Jun FENG
				Group Art Unit	1624
				Examiner Name	Kahsay Habte
				Attorney Docket Number	SYR-DPP-IV-5004-U

LC	WO 03/024965	3/27/2003	NOVO NORDISK A/S		
LD	WO 03/035067	5/1/2003	FERRING B.V.		
LE	WO 03/037327	5/8/2003	F. HOFFMANN-LA ROCHE AG		
LF	WO 03/038123	5/8/2003	NOVARTIS AG		
LG	WO 03/040114	5/15/2003	BRISTOL-MYERS SQUIBB COMPANY		
LH	WO 03/051848	6/26/2003	FERRING BV		
LI	WO 03/053330	3/7/2003	ASTRAZENECA AB		
LJ	WO 03/055881	7/10/2003	F. HOFFMANN-LA ROCHE AG		
LK	WO 03/057144	7/17/2003	GUILFORD PHARMACEUTICALS		
LL	WO 03/057686	7/17/2003	GUILFORD PHARMACEUTICALS		
LM	WO 03/055983	8/14/2003	MERCK & CO., INC.		
LN	WO 03/068748	8/21/2003	F. HOFFMANN-LA ROCHE AG		
LO	WO 03/068757	8/21/2003	F. HOFFMANN-LA ROCHE AG		
LP	WO 03/072197	9/4/2003	Pfizer Products Inc.		
LQ	WO 03/074500	9/12/2003	SANOFI-SYNTHELABO		
LR	WO 03/076393	9/18/2003	NOVARTIS AG		
LS	WO 03/077935	9/25/2003	IMTM INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH		
LT	WO 03/080070	10/2/2003	NOVARTIS AG		
LU	WO 03/080633	10/2/2003	NIPPON KAYAKU KABUSHIKI KAISHA		
LV	WO 03/082817	10/9/2003	MERCK & CO., INC.		
LW	WO 03/082859	10/9/2003	NOVARTIS AG		
LX	WO 03/084940	10/16/2003	SANKARANARAYANAN, Alangudi		
LY	WO 03/101449	12/11/2003	Pfizer Products Inc.		
LZ	WO 03/101958	12/11/2003	Pfizer Products Inc.		
MA	WO 03/104207	12/18/2003	MERCK & CO., INC.		
MB	WO 03/104208	12/18/2003	MERCK & CO., INC.		
MC	WO 03/104229	12/18/2003	EISAI CO., LTD.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.38. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form. Response times may vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

12

of

14

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

ND	WO 04/048352	6/10/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
NE	WO 04/050022	6/17/2004	MERCK & CO., INC.		
NF	WO 04/050656	6/17/2004	EISAI CO., LTD.		
NG	WO 04/050658	6/17/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
NH	WO 04/052850	6/24/2004	BRISTOL-MYERS SQUIBB COMPANY		
NI	WO 04/058266	7/15/2004	MERCK & CO., INC.		
NJ	WO 04/064778	8/5/2004	MERCK & CO., INC.		
NK	WO 04/067509	8/12/2004	SANWA KAGAKU KENKYUSHO CO., LTD.		
NL	WO 04/069162	8/19/2004	MERCK & CO., INC.		
NM	WO 04/071454	8/26/2004	GUILFORD PHARMACEUTICALS INC.		
NN	WO 04/075515	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
NO	WO 04/075891	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
NP	WO 04/076401	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
NQ	WO 04/076433	9/10/2004	AIC		
NR	WO 04/076434	9/10/2004	AIC		
NS	WO 04/078777	9/16/2004	BIOREXIS PHARMACEUTICAL CORPORATION		
NT	WO 04/080958	9/23/2004	MERCK & CO. INC.		
NU	WO 04/083212	9/30/2004	MERCK & CO., INC.		
NV	WO 04/085661	10/7/2004	MERCK & CO., INC.		
NW	WO 04/087053	10/14/2004	SYRRX, INC.		
NX	WO 04/087850	10/14/2004	MERCK & CO. INC.		
NY	WO 04/087880	10/14/2004	AYERZ PHARMACEUTICALS CORPORATION		
NZ	WO 04/089362	10/21/2004	NOVO NORDISK A/S		
OA	WO 04/096806	11/11/2004	SUMITOMO PHARMACEUTICALS CO., LTD.		
OB	WO 04/098625	11/19/2004	PROBIODRUG AG		
OC	WO 04/099134	11/19/2004	PROSIDION LTD.		
OD	WO 04/099185	11/19/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
OE	WO 04/101514	11/25/2004	TAISHO PHARMACEUTICAL CO., LTD.		
OF	WO 04/103276	12/2/2004	MERCK & CO., INC.		
OG	WO 04/103993	12/2/2004	SYRRX, INC.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and maintaining the data. Response to this form is required for filing an application to the USPTO. Time will vary depending upon the individual case. Any comments or the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			<i>Complete If Known</i>	
			Application Number	10/809,635
			Filing Date	March 24, 2004
			First Named Inventor	Jun FENG
			Group Art Unit	1624
			Examiner Name	Kahsay Habte
Sheet	13	of	14	Attorney Docket Number
			SYR-DPP-IV-5004-U	

OH	WO 04/110436	12/23/2004	MERCK & CO., INC.		
OI	WO 04/111041	12/23/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
OJ	WO 04/111051	12/23/2004	BOEHRINGER INGELHEIM INTERNATIONAL GMBH		
OK	WO 04/112701	12/29/2004	MERCK & CO., INC.		
OL	WO 05/000846	1/6/2005	F.HOFFMANN-LA ROCHE AG		
OM	WO 05/003135	1/13/2005	MERCK & CO., INC.		
ON	WO 05/011581	2/10/2005	MERCK & CO., INC.		
OO	WO 05/012249	2/10/2005	BRISTOL-MYERS SQUIBB COMPANY		
OP	WO 05/019168	3/3/2005	PFIZER PRODUCTS INC.		
OQ	WO 2005/016911	2/24/2005	Syrrx, Inc.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
OR	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335064. Database Accession no. 1447881 & J. HETEROCYCLOCHEM., Vol. 305, 1972, pages 724-730.		
OS	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335065. Database Accession no. 1447134 & J.ORG.CHEM., Vol. 43, 1978, pages 4069-4074.		
OT	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335066. Database Accession no. 386882 & J.CHEM.SOC., 1952, pages 4985-4990.		
OU	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335067. Database Accession no. 389578 & CHEM.BER., Vol. 88, 1968, pages 106-109.		
OV	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335068. Database Accession no. 472441 & YAKUGAKU ZASSHI, Vol. 88, 1968, pages 106-109.		
OW	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335069. Database Accession no. 1447840 & CHEM.BER., Vol. 101, No. 6, 1968, pages 2679-2689.		
OX	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335070. Database Accession no. 1448669 & CHEM.BER., Vol. 101, No. 8, 1968, pages 2679-2689.		
OY	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335071. Database Accession no. 4991064, J.CHEM.SOC.PERKIN TRANS.1, 1980, pages 1370-1380.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is a fee (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, filling out, reviewing and signing the form. This burden does not include the time spent in interviewing, consulting, or otherwise working with the USPTO. Persons who are disabled or have difficulty reading or completing this form may request reasonable accommodation on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

14

of

14

Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

OZ	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335072. Database Accession no. 990008, J.PRAKT.CHEM., Vol. 315, 1973, pages 1168-1168.	
PA	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335073. Database Accession no. 6219070, J.PRAKT.CHEM., Vol. 330, No. 2, 1988, pages 323-324.	
PB	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335074. Database Accession no. 392446, LHETERO CYCL.CHEM., Vol. 8, 1971, pages 367-371.	
PC	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335075. Database Accession no. 4742608, J. PRAKT.CHEM., Vol. 333, No. 1, 1991, pages 149-151.	
PD	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335076. Database Accession no. 490809, & ANGEW.CHEM., Vol. 84, 1972, page 1185.	
PE	Database Crossfire Bellstein Institut zur Förderung der Wissenschaften, Frankfurt am Main, DE; XP002335063. Database Accession no. 1525341 & J. HETERO CYCL.CHEM., Vol. 12, 1975, pages 683-687.	
PF	GUPTA, A. et al.: "Fluorine containing Biologically Active Agents: Synthesis of some new Pyrimidine Derivatives" J.IND. CHEM.SOC., Vol. 71 1994, pages 635-638, XP000889664 compound 1	
PG	Kesarwani, A. P. et al.: Solid-phase synthesis of quinazolin-(3H)-ones with three-point diversity, Tetrahedron Letters, Vol. 43, (2002) pp. 5579-5581.	
PH	Reuchman, B.S. et al. "2,4-Diamino-5-benzylypyrimidines and Analogues as antibacterial Agents", Journal of Med. Chem., Vol. 23, 1980, pages 384-391, XP02335048 Scheme II	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to enable the USPTO to retain a record by the public which is to be made available to the public (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and maintaining the data. This burden will vary depending upon the individual circumstances. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.